 | | Vol. 7.37 – 25 October, 2021 |
| |
|
|
| Investigators showed that in mouse melanoma models, depleted KDM5B — an H3K4 demethylase that was critical for melanoma maintenance and drug resistance — induced robust adaptive immune responses and enhanced responses to immune checkpoint blockades.
[Nature] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| | DERMAL STEM CELLS & TISSUE REGENERATION |
|
|
|
| Researchers confirmed the downregulation of miR-193b-3p in psoriasis patients, psoriasis-like inflammatory cellular models, and an imiquimod-induced mouse model.
[Cell Death & Disease] |
|
|
|
| The authors systematically profiled chromatin accessibility on Th1, Th2, Th1-17, Th17, and Treg cells and found that chromatin remodeling contributed significantly to the pathogenesis of the disease.
[Frontiers of Medicine] |
| |
|
|
| Scientists explained the specificity of the role of mammalian SWI/SNF (BAF) subunit actin-like 6a (ACTL6A) amplification in squamous cell carcinomas and demonstrated that ACTL6A overexpression led to its stoichiometric assembly into BAF complexes.
[Molecular Cell] |
|
|
|
| Investigators reported that mucolipin TRP channel 1, a lysosomal Ca2+ and Zn2+ release channel that regulated multiple aspects of lysosome function, was dramatically upregulated in metastatic melanoma cells compared to normal cells.
[Cell Reports] |
|
|
|
| Researchers used a DNA-methylation pattern approach and uncovered evidence regarding the cell of origin of classical virus-associated merkel cell carcinomas (MCC) and virus-negative MCCs that were driven by UV-light-induced mutation cell lines, that is, cell lines with a neuroendocrine growth pattern.
[Oncogene] |
|
|
|
| The long non-coding RNA, HOX antisense intergenic RNA (HOTAIR), was a well-characterized oncogene in multiple human cancers, but not in cutaneous squamous cell carcinoma (CSCC). The authors investigated the potential role of HOTAIR in the stemness of CSCC.
[Oncogene] |
|
|
|
| Scientists demonstrated that kinectin1 knockdown induced epidermal growth factor receptor (EGFR) degradation in cutaneous squamous cell carcinoma cells and promoted the ubiquitin-proteasome system, and that this effect was tumor cell-specific.
[Cell Death & Disease] |
|
|
|
| Investigators confirmed the superior efficacy of linogel in terms of marked improvement in the nucleus and subcellular structures in photomicrographs, through histopathological and ultrastructural analysis, which fulfilled all the criteria of dermal application.
[International Journal of Pharmaceutics] |
|
|
|
| Researchers clarified how NKIRAS acted on cellular transformation, and generated transgenic mice in which NKIRAS2 was forcibly expressed using a cytokeratin 15 promoter, which was mainly activated in follicle bulge cells.
[Scientific Reports] |
|  |
|
|
|
| The authors introduce neutrophil extracellular trap formation and discuss the possible neutrophil extracellular trap-related mechanisms in wound healing.
[Cell Death & Disease] |
|
|
|
| Investigators summarize experimental studies evaluating in vitro efficacy of water-only or soap and water in decontaminating chemical warfare agents or their simulants from human skin models.
[Journal of Applied Toxicology] |
|
|
|
| Scientists review the clinical efficacy of secukinumab during the first 12 weeks of treatment. They found treatment with secukinumab improves health-related quality of life and is generally well tolerated.
[Pediatric Drugs] |
|
|
|
|
| Regeneron Pharmaceuticals, Inc. and Sanofi announced positive pivotal Phase III results from a trial evaluating Dupixent® in adults with uncontrolled prurigo nodularis, a chronic type 2 inflammatory skin disease that causes extreme itch and skin lesions.
[Regeneron Pharmaceuticals, Inc.] |
|
|
|
| DICE Therapeutics, Inc. announced that the first healthy volunteer has been dosed in the company’s Phase I clinical trial of S011806, designed to generate safety and pharmacokinetic data, as well as provide early clinical proof-of-concept in psoriasis patients.
[DICE Therapeutics, Inc.] |
|
|
|
|
| November 9 – 10, 2021
Montpellier, France |
|
|
|
|
|
| | Columbia University Medical Center – New York, New York, United States |
|
|
|
| | Cancer Research UK Manchester Institute – Manchester, United Kingdom |
|
|
|
| | The University of New Mexico – Albuquerque, New Mexico, United States |
|
|
|
| | Novo Nordisk – Indianapolis, Indiana, United States |
|
|
|
| | University of Minnesota – Austin, Minnesota, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
